Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Chronic Heart Failure

  Free Subscription


Articles published in Eur J Heart Fail

Retrieve available abstracts of 452 articles:
HTML format
Text format



Single Articles


    October 2018
  1. MCDONAGH T, Damy T, Doehner W, Lam CSP, et al
    Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice.
    Eur J Heart Fail. 2018 Oct 12. doi: 10.1002/ejhf.1305.
    PubMed     Text format     Abstract available


  2. COSTANZO MR, Ponikowski P, Coats A, Javaheri S, et al
    Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure.
    Eur J Heart Fail. 2018 Oct 10. doi: 10.1002/ejhf.1312.
    PubMed     Text format     Abstract available


  3. PATEL HC, Kaye DM
    Exercise training in heart failure: a long way to go yet.
    Eur J Heart Fail. 2018 Oct 9. doi: 10.1002/ejhf.1332.
    PubMed     Text format    


  4. MCCARTHY CP, Vaduganathan M, Pandey A
    Developing evidence-based and accountable health policy in heart failure.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1331.
    PubMed     Text format    


  5. CAMPBELL RT, Petrie MC, McMurray JJV
    Talking to patients with heart failure about end of life.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1321.
    PubMed     Text format    


  6. STRENG KW, Lang CC, Voors AA
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1324.
    PubMed     Text format    


  7. PAPP Z, Radovits T, Paulus WJ, Hamdani N, et al
    Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus.
    Eur J Heart Fail. 2018 Oct 2. doi: 10.1002/ejhf.1318.
    PubMed     Text format    


  8. CORRA U, Agostoni PG, Anker SD, Coats AJS, et al
    Corrigendum to 'Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology' [Eur
    Eur J Heart Fail. 2018;20:1501.
    PubMed     Text format    


    September 2018
  9. TAYLOR RS, Walker S, Smart NA, Piepoli MF, et al
    Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials.
    Eur J Heart Fail. 2018 Sep 26. doi: 10.1002/ejhf.1311.
    PubMed     Text format     Abstract available


  10. MULLENS W, Verbrugge FH, Nijst P, Martens P, et al
    Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
    Eur J Heart Fail. 2018 Sep 21. doi: 10.1002/ejhf.1307.
    PubMed     Text format     Abstract available


  11. KOEHLER F, Koehler K, Deckwart O, Prescher S, et al
    Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and descrip
    Eur J Heart Fail. 2018 Sep 19. doi: 10.1002/ejhf.1300.
    PubMed     Text format     Abstract available


  12. GREENBERG B, Fang J, Mehra M, Stevenson LW, et al
    Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1313.
    PubMed     Text format    


  13. VENTURA HO, Carbone S, Lavie CJ
    Muscling up to improve heart failure prognosis.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1314.
    PubMed     Text format    


  14. PACKER M
    The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1294.
    PubMed     Text format    


  15. VOORS AA, Shah SJ, Bax JJ, Butler J, et al
    Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1295.
    PubMed     Text format     Abstract available


  16. BOUABDALLAOUI N, Claggett B, Zile MR, McMurray JJV, et al
    Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
    Eur J Heart Fail. 2018 Sep 11. doi: 10.1002/ejhf.1301.
    PubMed     Text format     Abstract available


  17. FISCHER TH, Eiringhaus J, Dybkova N, Saadatmand A, et al
    Activation of protein phosphatase 1 by a selective phosphatase disrupting peptide reduces sarcoplasmic reticulum Ca(2+) leak in human heart failure.
    Eur J Heart Fail. 2018 Sep 7. doi: 10.1002/ejhf.1297.
    PubMed     Text format     Abstract available


  18. PALECZNY B, Olesinska-Mader M, Siennicka A, Niewinski P, et al
    Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival.
    Eur J Heart Fail. 2018 Sep 6. doi: 10.1002/ejhf.1306.
    PubMed     Text format     Abstract available


  19. METRA M
    September 2018 at a glance: co-morbidities, heart failure with preserved ejection fraction and mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018;20:1245-1246.
    PubMed     Text format    


    August 2018
  20. LUO N, O'Connor CM, Cooper LB, Sun JL, et al
    Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.
    Eur J Heart Fail. 2018 Aug 31. doi: 10.1002/ejhf.1299.
    PubMed     Text format     Abstract available


  21. EMAMI A, Saitoh M, Valentova M, Sandek A, et al
    Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
    Eur J Heart Fail. 2018 Aug 30. doi: 10.1002/ejhf.1304.
    PubMed     Text format     Abstract available


  22. CAO TH
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure?
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1303.
    PubMed     Text format    


  23. GODINO C, Scotti A, Munafo A, Taramasso M, et al
    Observed versus predicted mortality after MitraClip treatment in patients with symptomatic heart failure and significant functional mitral regurgitation.
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1291.
    PubMed     Text format    


  24. TROMP J, Teng TH, Tay WT, Hung CL, et al
    Heart failure with preserved ejection fraction in Asia.
    Eur J Heart Fail. 2018 Aug 16. doi: 10.1002/ejhf.1227.
    PubMed     Text format     Abstract available


  25. GRAZIANI F, Varone F, Crea F, Richeldi L, et al
    Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis.
    Eur J Heart Fail. 2018 Aug 7. doi: 10.1002/ejhf.1286.
    PubMed     Text format     Abstract available


  26. GAGLIARDI C, Perfetto F, Lorenzini M, Ferlini A, et al
    Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Eur J Heart Fail. 2018 Aug 2. doi: 10.1002/ejhf.1285.
    PubMed     Text format     Abstract available


  27. VAN WOERDEN G, Gorter TM, Daan Westenbrink B, Willems TP, et al
    Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.
    Eur J Heart Fail. 2018 Aug 1. doi: 10.1002/ejhf.1283.
    PubMed     Text format     Abstract available


    July 2018
  28. MAGINI A, Farina S, Riggio D, Sandri MT, et al
    ST2 and B-type natriuretic peptide kinetics during exercise in severe heart failure.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1246.
    PubMed     Text format    


  29. COTTER G, Davison BA
    Unmodifiable events, heart failure research, and 'risk-based monitoring' in large studies-the unholy triumvirate.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1282.
    PubMed     Text format    


  30. SCHMITTO JD, Pya Y, Zimpfer D, Krabatsch T, et al
    Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1284.
    PubMed     Text format     Abstract available


  31. DOEHNER W, Celutkiene J, Haeusler KG
    Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation? Reply.
    Eur J Heart Fail. 2018 Jul 13. doi: 10.1002/ejhf.1281.
    PubMed     Text format    


  32. CARBONE S, Elagizi A, Lavie CJ
    Obesity and mortality risk in heart failure: when adipose tissue distribution matters.
    Eur J Heart Fail. 2018 Jul 12. doi: 10.1002/ejhf.1279.
    PubMed     Text format    


  33. MAHMOOD SS, Patel RB, Butler J, Vaduganathan M, et al
    Epirubicin and long-term heart failure risk in breast cancer survivors.
    Eur J Heart Fail. 2018 Jul 4. doi: 10.1002/ejhf.1215.
    PubMed     Text format    


  34. STRENG KW, Voors AA, Hillege HL, Anker SD, et al
    Waist-to-hip ratio and mortality in heart failure.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1244.
    PubMed     Text format     Abstract available


  35. JAARSMA T, van der Wal M, Hjelmfors L, Stromberg A, et al
    Talking about palliative care in heart failure.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1239.
    PubMed     Text format    


  36. PATEL KV, Pandey A
    Prognostic implications of microvascular complications in patients with diabetes and heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1253.
    PubMed     Text format    


  37. METRA M
    July 2018 at a glance: practical guidance in acute heart failure, pathophysiology and clinical trials of medical therapy.
    Eur J Heart Fail. 2018;20:1079-1080.
    PubMed     Text format    


    June 2018
  38. CAMPBELL RT, Petrie MC, Jackson CE, Jhund PS, et al
    Which patients with heart failure should receive specialist palliative care?
    Eur J Heart Fail. 2018 Jun 28. doi: 10.1002/ejhf.1240.
    PubMed     Text format     Abstract available


  39. COOPER LB, Yap J, Tay WT, Teng TK, et al
    Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1223.
    PubMed     Text format     Abstract available


  40. ANKER MS, von Haehling S, Landmesser U, Coats AJS, et al
    Cancer and heart failure-more than meets the eye: common risk factors and co-morbidities.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1252.
    PubMed     Text format    


  41. CUTHBERT JJ, Pellicori P, Rigby A, Pan D, et al
    Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1247.
    PubMed     Text format     Abstract available


  42. SIMONOVIC D, Coiro S, Carluccio E, Girerd N, et al
    Exercise elicits dynamic changes in extravascular lung water and haemodynamic congestion in heart failure patients with preserved ejection fraction.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1228.
    PubMed     Text format    


  43. PASCUAL-FIGAL D, Bayes-Genis A
    The misperception of 'stable' heart failure.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1248.
    PubMed     Text format    


  44. PATEL RB, Vaduganathan M, Greene SJ, Butler J, et al
    Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1231.
    PubMed     Text format    


  45. VACCARO O, Riccardi G, Maggioni AP
    Risk of heart failure in diabetic patients receiving sulfonylureas.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1238.
    PubMed     Text format    


  46. AMBROSY AP, Chioncel O
    Combination drug therapy in heart failure: greater than the sum of its parts.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1251.
    PubMed     Text format    


  47. KREMER D, Ter Maaten JM, Voors AA
    Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1245.
    PubMed     Text format    


  48. OBOKATA M, Borlaug BA
    The strengths and limitations of E/e' in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1250.
    PubMed     Text format    


  49. IORIO A, Senni M, Barbati G, Greene SJ, et al
    Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Eur J Heart Fail. 2018 Jun 19. doi: 10.1002/ejhf.1202.
    PubMed     Text format     Abstract available


  50. WOLSK E
    Heart failure and co-morbidity revisited; the elephant in the room.
    Eur J Heart Fail. 2018 Jun 19. doi: 10.1002/ejhf.1225.
    PubMed     Text format    


  51. GRODIN JL, Testani JM, Pandey A, Sambandam K, et al
    Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Eur J Heart Fail. 2018 Jun 12. doi: 10.1002/ejhf.1229.
    PubMed     Text format     Abstract available


  52. SOKORELI I, Pauws SC, Riistama JM, Cleland JG, et al
    Psychosocial factors and mortality in patients with heart failure: reply.
    Eur J Heart Fail. 2018 Jun 12. doi: 10.1002/ejhf.1224.
    PubMed     Text format    


  53. NAGAI M, Dote K, Kato M
    Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation?
    Eur J Heart Fail. 2018 Jun 11. doi: 10.1002/ejhf.1233.
    PubMed     Text format    


  54. PACKER M
    Risk of heart failure in diabetic patients receiving sulfonylureas: reply.
    Eur J Heart Fail. 2018 Jun 11. doi: 10.1002/ejhf.1232.
    PubMed     Text format    


  55. BUTLER J, Vijayakumar S, Pitt B
    Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018 Jun 8. doi: 10.1002/ejhf.1217.
    PubMed     Text format    


  56. NAUTA JF, Hummel YM, van der Meer P, Lam CSP, et al
    Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patient
    Eur J Heart Fail. 2018 Jun 7. doi: 10.1002/ejhf.1220.
    PubMed     Text format     Abstract available


  57. METRA M
    June 2018 at a glance: peripartum cardiomyopathy and pathophysiology, prognosis, and device therapy of heart failure.
    Eur J Heart Fail. 2018;20:949-950.
    PubMed     Text format    


    May 2018
  58. KONSTAM MA
    Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1205.
    PubMed     Text format    


  59. ROSSIGNOL P, Ferreira JP, Zannad F
    Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1214.
    PubMed     Text format    


  60. GREENBERG B
    Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1222.
    PubMed     Text format    


  61. LAUFS U, Griese-Mammen N, Krueger K, Wachter A, et al
    PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study.
    Eur J Heart Fail. 2018 May 30. doi: 10.1002/ejhf.1213.
    PubMed     Text format     Abstract available


  62. NAGAI T, Sundaram V, Shoaib A, Shiraishi Y, et al
    Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan.
    Eur J Heart Fail. 2018 May 30. doi: 10.1002/ejhf.1210.
    PubMed     Text format     Abstract available


  63. KOMAJDA M, Bohm M, Borer JS, Ford I, et al
    Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.
    Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1234.
    PubMed     Text format     Abstract available


  64. CRESPO-LEIRO MG, Metra M, Lund LH, Milicic D, et al
    Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1236.
    PubMed     Text format     Abstract available


  65. SHARMA A, Al-Khatib SM, Ezekowitz JA, Cooper LB, et al
    Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Eur J Heart Fail. 2018 May 15. doi: 10.1002/ejhf.1192.
    PubMed     Text format     Abstract available


  66. KRISTENSEN SL, Rorth R, Jhund PS, Shen L, et al
    Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial.
    Eur J Heart Fail. 2018 May 4. doi: 10.1002/ejhf.1201.
    PubMed     Text format     Abstract available


  67. KORATALA A
    Metabolic abnormalities in heart failure patients treated with ultrafiltration versus diuretics.
    Eur J Heart Fail. 2018 May 3. doi: 10.1002/ejhf.1207.
    PubMed     Text format    



  68. Abstracts of the Heart Failure 2018 and the World Congress on Acute Heart Failure, 26-29 May 2018, Vienna, Austria.
    Eur J Heart Fail. 2018;20 Suppl 1:5-638.
    PubMed     Text format    


    April 2018
  69. HARJOLA VP, Parissis J, Brunner-La Rocca HP, Celutkiene J, et al
    Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Ca
    Eur J Heart Fail. 2018 Apr 30. doi: 10.1002/ejhf.1204.
    PubMed     Text format     Abstract available


  70. RAVASSA S, Trippel T, Bach D, Bachran D, et al
    Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Eur J Heart Fail. 2018 Apr 30. doi: 10.1002/ejhf.1194.
    PubMed     Text format     Abstract available


  71. KAWADA T
    Psychosocial factors and mortality in patients with heart failure.
    Eur J Heart Fail. 2018 Apr 24. doi: 10.1002/ejhf.1208.
    PubMed     Text format    


  72. VAN VELDHUISEN DJ, Rienstra M, van der Meer P
    Value of digoxin in patients with heart failure: new pieces to the puzzle.
    Eur J Heart Fail. 2018 Apr 20. doi: 10.1002/ejhf.1200.
    PubMed     Text format    


  73. CERLINSKAITE K, Hollinger A, Mebazaa A, Cinotti R, et al
    Finding the balance between costs and quality in heart failure: a global challenge.
    Eur J Heart Fail. 2018 Apr 19. doi: 10.1002/ejhf.1195.
    PubMed     Text format    


  74. ALLA F, Agrinier N, Lavielle M, Rossignol P, et al
    Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population-based study.
    Eur J Heart Fail. 2018 Apr 16. doi: 10.1002/ejhf.1193.
    PubMed     Text format    


  75. DOEHNER W, Ural D, Celutkiene J
    Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity: reply.
    Eur J Heart Fail. 2018 Apr 14. doi: 10.1002/ejhf.1177.
    PubMed     Text format    


  76. KLEBER FX, Koln PJ
    Oxygen consumption trajectory flattening-yet another cardiopulmonary exercise testing parameter in chronic heart failure.
    Eur J Heart Fail. 2018 Apr 14. doi: 10.1002/ejhf.1181.
    PubMed     Text format    


  77. GRODIN JL, Tang WHW
    I will take my heart failure 'lactate-free' please.
    Eur J Heart Fail. 2018 Apr 10. doi: 10.1002/ejhf.1190.
    PubMed     Text format    


    March 2018
  78. PACKER M
    Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1185.
    PubMed     Text format     Abstract available


  79. FUDIM M, Mentz RJ
    Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1189.
    PubMed     Text format    


  80. KIMURA M, Kohno T, Yoshikawa T
    Early versus late readmission during the vulnerable phase following hospitalization for heart failure.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1179.
    PubMed     Text format    


  81. SLIWA K, Petrie MC, Hilfiker-Kleiner D, Mebazaa A, et al
    Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy.
    Eur J Heart Fail. 2018 Mar 26. doi: 10.1002/ejhf.1178.
    PubMed     Text format     Abstract available


  82. SAVARESE G, Carrero JJ, Pitt B, Anker SD, et al
    Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2018 Mar 26. doi: 10.1002/ejhf.1182.
    PubMed     Text format     Abstract available


  83. PACKER M
    Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications.
    Eur J Heart Fail. 2018 Mar 22. doi: 10.1002/ejhf.1183.
    PubMed     Text format     Abstract available


  84. MAGKOUTIS N, Mantzaraki V, Farmakis D, Spathis A, et al
    Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factor-A in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2018 Mar 14. doi: 10.1002/ejhf.1176.
    PubMed     Text format    


  85. SEFEROVIC PM, Petrie MC, Filippatos GS, Anker SD, et al
    Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1170.
    PubMed     Text format     Abstract available


  86. FERRARI R, Bueno H, Chioncel O, Cleland JG, et al
    Acute heart failure: lessons learned, roads ahead.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1169.
    PubMed     Text format    


  87. AVOGARO A, Fadini GP
    Insulin treatment in patients with diabetes and heart failure: defendant on the stand.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1161.
    PubMed     Text format    


  88. DEMISSEI BG, Voors AA
    Risk stratification in acute heart failure: reply.
    Eur J Heart Fail. 2018 Mar 7. doi: 10.1002/ejhf.1171.
    PubMed     Text format    


  89. SILISTE RN, Antohi EL, Pepoyan S, Nakou E, et al
    Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice.
    Eur J Heart Fail. 2018 Mar 5. doi: 10.1002/ejhf.1153.
    PubMed     Text format     Abstract available


  90. WOLDMAN S
    Heart failure management-time to change our script on prognosis?
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1157.
    PubMed     Text format    


  91. PACKER M
    Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1167.
    PubMed     Text format     Abstract available


  92. GRODIN JL, Carter S, Bart BA, Goldsmith SR, et al
    Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1158.
    PubMed     Text format     Abstract available


  93. ABDUL-RAHIM AH, Shen L, Rush CJ, Jhund PS, et al
    Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1160.
    PubMed     Text format     Abstract available


  94. LUND LH, Pitt B
    Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1175.
    PubMed     Text format    


  95. BANKE A, Fosbol EL, Moller JE, Gislason GH, et al
    Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1168.
    PubMed     Text format     Abstract available


    February 2018
  96. COSMI F, Shen L, Magnoli M, Abraham WT, et al
    Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.
    Eur J Heart Fail. 2018 Feb 28. doi: 10.1002/ejhf.1146.
    PubMed     Text format     Abstract available


  97. AMERI P, Canepa M, Anker MS, Belenkov Y, et al
    Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.
    Eur J Heart Fail. 2018 Feb 21. doi: 10.1002/ejhf.1165.
    PubMed     Text format     Abstract available


  98. LINDGREN M, Eriksson P, Rosengren A, Robertson J, et al
    Cognitive performance in late adolescence and long-term risk of early heart failure in Swedish men.
    Eur J Heart Fail. 2018 Feb 19. doi: 10.1002/ejhf.1163.
    PubMed     Text format     Abstract available


  99. MADIAS JE
    Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1150.
    PubMed     Text format    


  100. LEVY WC, Dardas TF
    Comparison of cardiopulmonary-based risk models with a clinical heart failure risk model.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1164.
    PubMed     Text format    


  101. AKIYAMA E, Van Aelst LNL, Arrigo M, Lassus J, et al
    East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1152.
    PubMed     Text format    


  102. ZYMLINSKI R, Biegus J, Sokolski M, Siwolowski P, et al
    Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1156.
    PubMed     Text format     Abstract available


  103. LUND LH, Claggett B, Liu J, Lam CS, et al
    Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1149.
    PubMed     Text format     Abstract available


  104. MOGENSEN UM, Gong J, Jhund PS, Shen L, et al
    Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1139.
    PubMed     Text format     Abstract available


  105. COMIN-COLET J, Manito N, Segovia-Cubero J, Delgado J, et al
    Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1145.
    PubMed     Text format     Abstract available


  106. ORBAN M, Besler C, Braun D, Nabauer M, et al
    Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1147.
    PubMed     Text format     Abstract available


  107. POPOVIC D, Arena R, Guazzi M
    A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1140.
    PubMed     Text format     Abstract available


  108. METRA M
    February 2018 at a glance: heart and brain interaction, prognostic variables, and acute heart failure and post-discharge outcomes.
    Eur J Heart Fail. 2018;20:191-192.
    PubMed     Text format    


  109. LEON JIMENEZ D, Gomez Huelgas R, Miramontes Gonzalez JP
    The mechanism of action of sodium-glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors.
    Eur J Heart Fail. 2018;20:409.
    PubMed     Text format    


  110. SPIRITO P, Ferrazzi P
    We need more high-volume myectomy centres in Europe.
    Eur J Heart Fail. 2018;20:406-408.
    PubMed     Text format    


  111. ROSENKRANZ S, Hoeper MM
    Pulmonary vascular indices and survival in left heart disease: illusion of conclusion?
    Eur J Heart Fail. 2018;20:256-259.
    PubMed     Text format    


  112. LUND LH
    Optimizing outcomes after heart transplantation.
    Eur J Heart Fail. 2018;20:395-397.
    PubMed     Text format    


  113. STEVENSON LW, Schneiweiss S, Gilstrap L
    Propensity to match or mismatch patients and therapies?
    Eur J Heart Fail. 2018;20:355-358.
    PubMed     Text format    


    January 2018
  114. TROMP J, Voors AA, Lam CSP
    Heart failure with mid-range ejection fraction: causes and consequences.
    Eur J Heart Fail. 2018 Jan 16. doi: 10.1002/ejhf.1134.
    PubMed     Text format    


  115. TROMP J, van der Meer P
    Predicting heart failure: one size does not fit all.
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1120.
    PubMed     Text format    


  116. LUND LH, Vedin O, Savarese G
    Is ejection fraction in heart failure a limitation or an opportunity?
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1106.
    PubMed     Text format    


  117. COSTANZO MR
    Uric acid is important, but there is something that matters even more: to deliver sacubitril/valsartan to eligible heart failure patients.
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1087.
    PubMed     Text format    


  118. ARQUES S
    Myocardial oedema and congestive heart failure: one piece of the puzzle?
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1121.
    PubMed     Text format    


  119. BEUSEKAMP JC, Tromp J, van der Wal HH, Anker SD, et al
    Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1079.
    PubMed     Text format     Abstract available


  120. GORTER TM, de Boer RA
    Myocardial oedema and congestive heart failure: one piece of the puzzle? Reply.
    Eur J Heart Fail. 2018 Jan 10. doi: 10.1002/ejhf.1136.
    PubMed     Text format    


  121. DONAL E, Galli E
    Clinical relevance of spectral tissue Doppler-derived E/e' in the diagnosis of heart failure with preserved ejection fraction: reply.
    Eur J Heart Fail. 2018 Jan 8. doi: 10.1002/ejhf.1090.
    PubMed     Text format    


  122. LUND LH
    Complex relationships between co-morbidity, outcomes, and treatment effect in heart failure.
    Eur J Heart Fail. 2018 Jan 5. doi: 10.1002/ejhf.1107.
    PubMed     Text format    


  123. DE ROSA S, Eposito F, Carella C, Strangio A, et al
    Transcoronary concentration gradients of circulating microRNAs in heart failure.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1119.
    PubMed     Text format     Abstract available


  124. MCDONALD K, Troughton R, Dahlstrom U, Dargie H, et al
    Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1053.
    PubMed     Text format     Abstract available


  125. MELE D, Nardozza M, Ferrari R
    Left ventricular ejection fraction and heart failure: an indissoluble marriage?
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1071.
    PubMed     Text format    


  126. BREIDTHARDT T, Moreno-Weidmann Z, Uthoff H, Sabti Z, et al
    How accurate is clinical assessment of neck veins in the estimation of central venous pressure in acute heart failure? Insights from a prospective study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1111.
    PubMed     Text format    


  127. AMBROSY AP, Fudim M, Chioncel O
    Sudden cardiac death following admission for acute heart failure: adding insult to injury.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1109.
    PubMed     Text format    


  128. FERREIRA JP, Duarte K, Pfeffer MA, McMurray JJV, et al
    Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarct
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1131.
    PubMed     Text format     Abstract available


  129. SUZUKI H, Matsumoto Y, Ota H, Sugimura K, et al
    Structural brain abnormalities and cardiac dysfunction in patients with chronic heart failure.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1104.
    PubMed     Text format    


  130. SOKORELI I, Pauws SC, Steyerberg EW, de Vries GJ, et al
    Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1112.
    PubMed     Text format     Abstract available


  131. VADUGANATHAN M, Samman Tahhan A, Greene SJ, Okafor M, et al
    Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1130.
    PubMed     Text format    


  132. PACKER M
    Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial.
    Eur J Heart Fail. 2018;20:49-51.
    PubMed     Text format    


  133. SWEDBERG K
    Lessons for the monitoring of safety in clinical trials.
    Eur J Heart Fail. 2018;20:148.
    PubMed     Text format    


  134. CRESPO-LEIRO MG, Barge-Caballero E
    Heart transplantation and left ventricular assist systems. Not too early, not too late.
    Eur J Heart Fail. 2018;20:161-163.
    PubMed     Text format    


  135. BAR C, Thum T
    A long way for microRNAs to become meaningful prognostic biomarkers.
    Eur J Heart Fail. 2018;20:76-77.
    PubMed     Text format    


  136. GUSTAFSSON F
    Management of patients with cardiogenic shock on temporary mechanical circulatory support: urgent transplantation or on to the next pump?
    Eur J Heart Fail. 2018;20:187-189.
    PubMed     Text format    


    December 2017
  137. TKACZYSZYN M, Jankowska EA
    Iron deficiency and red cell indices in patients with heart failure: reply.
    Eur J Heart Fail. 2017 Dec 27. doi: 10.1002/ejhf.1092.
    PubMed     Text format    


  138. DOEHNER W, Ural D, Haeusler KG, Celutkiene J, et al
    Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association.
    Eur J Heart Fail. 2017 Dec 27. doi: 10.1002/ejhf.1100.
    PubMed     Text format     Abstract available


  139. ROSANO GMC, Seferovic P, Farmakis D, Filippatos G, et al
    Renin inhibition in heart failure and diabetes: the real story.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1072.
    PubMed     Text format    


  140. XANTHOPOULOS A, Tryposkiadis K, Giamouzis G, Konstantinou D, et al
    Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1132.
    PubMed     Text format    


  141. RAMALHO SHR, Shah AM
    Central sleep apnoea in heart failure with reduced ejection fraction, adaptive servo-ventilation, and left ventricular ejection fraction: the (still) missing link.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1108.
    PubMed     Text format    


  142. POKORNEY SD, Al-Khatib SM, Sun JL, Schulte P, et al
    Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.
    Eur J Heart Fail. 2017 Dec 20. doi: 10.1002/ejhf.1078.
    PubMed     Text format     Abstract available


  143. VAN AELST LNL, Arrigo M, Placido R, Akiyama E, et al
    Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1050.
    PubMed     Text format     Abstract available


  144. BISTOLA V, Polyzogopoulou E, Ikonomidis I, Parissis J, et al
    Congestion in acute heart failure with reduced vs. preserved left ventricular ejection fraction: differences, similarities and remaining gaps.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1115.
    PubMed     Text format    


  145. EMMENS JE, Jones DJL, Cao TH, Chan DCS, et al
    Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1101.
    PubMed     Text format     Abstract available


  146. LUPON J, Bayes-Genis A
    Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1116.
    PubMed     Text format    


  147. DELLES C, Rankin NJ, Boachie C, McConnachie A, et al
    Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.
    Eur J Heart Fail. 2017 Dec 11. doi: 10.1002/ejhf.1076.
    PubMed     Text format     Abstract available


  148. BHAMBHANI V, Kizer JR, Lima JAC, van der Harst P, et al
    Predictors and outcomes of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2017 Dec 11. doi: 10.1002/ejhf.1091.
    PubMed     Text format     Abstract available


  149. VON HAEHLING S
    Co-morbidities in heart failure beginning to sprout-and no end in sight?
    Eur J Heart Fail. 2017;19:1566-1568.
    PubMed     Text format    


    November 2017
  150. COWIE MR, Woehrle H, Wegscheider K, Vettorazzi E, et al
    Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1048.
    PubMed     Text format     Abstract available


  151. KHERA R, Pandey A
    The heart failure readmission quagmire: taking a deep dive to find solutions.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1082.
    PubMed     Text format    


  152. ARQUES S
    Clinical relevance of spectral tissue Doppler-derived E/e' in the diagnosis of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1084.
    PubMed     Text format    


  153. WOLSK E, Claggett B, Kober L, Pocock S, et al
    Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1073.
    PubMed     Text format     Abstract available


  154. SENNI M, McMurray JJV, Wachter R, McIntyre HF, et al
    Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
    Eur J Heart Fail. 2017 Nov 22. doi: 10.1002/ejhf.1054.
    PubMed     Text format     Abstract available


  155. ROSSING K, Gustafsson F
    Medical and mechanical unloading in advanced heart failure: hope for cardiac recovery?
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1081.
    PubMed     Text format    


  156. TAVAZZI L
    It's time to move on from counting co-morbidities to curing them: the case of chronic heart failure-chronic obstructive pulmonary disease co-morbidity.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1083.
    PubMed     Text format    


  157. GREENE SJ, Felker GM
    Considering the duration of heart failure: using the past to predict the future.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1064.
    PubMed     Text format    


  158. FARMAKIS D, Papingiotis G, Parissis J, Filippatos G, et al
    Ups and downs in heart failure: the case of proteomics.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1065.
    PubMed     Text format    


  159. SESSA M, Mascolo A, Mortensen RN, Andersen MP, et al
    Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
    Eur J Heart Fail. 2017 Nov 20. doi: 10.1002/ejhf.1045.
    PubMed     Text format     Abstract available


  160. RORTH R, Fosbol EL, Mogensen UM, Kragholm K, et al
    Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1046.
    PubMed     Text format     Abstract available


  161. GO YY, Sugimoto T, Bulluck H, Acharyya S, et al
    Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1075.
    PubMed     Text format    


  162. PALAU P, Dominguez E, Nunez J
    Clinical utility of cardiopulmonary exercise testing in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1066.
    PubMed     Text format    


  163. LOURENCO AP, Leite-Moreira AF, Balligand JL, Bauersachs J, et al
    An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1059.
    PubMed     Text format     Abstract available


  164. SELVARAJ S, Claggett B, Shah SJ, Anand I, et al
    Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1060.
    PubMed     Text format     Abstract available


  165. GHIO S, Crimi G, Temporelli PL, Traversi E, et al
    Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1067.
    PubMed     Text format     Abstract available


  166. ZENG DX
    Iron deficiency and red cell indices in patients with heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1052.
    PubMed     Text format    


  167. SCHNEIDER D, Flores D, Mueller C
    Risk stratification in acute heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1057.
    PubMed     Text format    


  168. VADUGANATHAN M, Cheema B, Cleveland E, Sankar K, et al
    Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  169. ARRIGO M, Mebazaa A
    Addressing vulnerability: opening a new door to improved outcomes in acute heart failure.
    Eur J Heart Fail. 2017 Nov 9. doi: 10.1002/ejhf.1063.
    PubMed     Text format    


  170. LAL S, Kotchetkova I, Cao J, Jackson D, et al
    Heart failure admissions and poor subsequent outcomes in adults with congenital heart disease.
    Eur J Heart Fail. 2017 Nov 7. doi: 10.1002/ejhf.1051.
    PubMed     Text format    


  171. CATINO AB, Ferrin P, Wever-Pinzon J, Horne BD, et al
    Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support.
    Eur J Heart Fail. 2017 Nov 1. doi: 10.1002/ejhf.1018.
    PubMed     Text format     Abstract available


    October 2017
  172. PACKER M
    Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?
    Eur J Heart Fail. 2017 Oct 30. doi: 10.1002/ejhf.1047.
    PubMed     Text format    


  173. CHEEMA B, Ambrosy AP, Kaplan RM, Senni M, et al
    Lessons learned in acute heart failure.
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1042.
    PubMed     Text format     Abstract available


  174. FUDIM M, O'Connor CM, Dunning A, Ambrosy AP, et al
    Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1020.
    PubMed     Text format     Abstract available


  175. GREENE SJ, Mentz RJ
    Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1024.
    PubMed     Text format    


  176. KELLY JP, DeVore AD
    Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home?
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1041.
    PubMed     Text format    


  177. BAJAJ NS, Claggett B, Lewis EF, Desai AS, et al
    Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Oct 25. doi: 10.1002/ejhf.1040.
    PubMed     Text format    


  178. NAUTA JF, Hummel YM, van Melle JP, van der Meer P, et al
    What have we learned about heart failure with mid-range ejection fraction one year after its introduction?
    Eur J Heart Fail. 2017 Oct 24. doi: 10.1002/ejhf.1058.
    PubMed     Text format     Abstract available


  179. PANICO C, Condorelli G
    microRNA-132: a new biomarker of heart failure at last?
    Eur J Heart Fail. 2017 Oct 20. doi: 10.1002/ejhf.1044.
    PubMed     Text format    


  180. PACKER M
    Why is the use of digitalis withering? Another reason that we need medical heart failure specialists.
    Eur J Heart Fail. 2017 Oct 19. doi: 10.1002/ejhf.1043.
    PubMed     Text format    


  181. STEWART COATS AJ
    Intravenous ferric carboxymaltose for heart failure with iron deficiency.
    Eur J Heart Fail. 2017 Oct 19. doi: 10.1002/ejhf.1027.
    PubMed     Text format    


  182. ROY B, Woo M, Kumar R
    Cerebral blood flow in central autonomic network: is there any effect of hemispheric lateralization in patients with heart failure? Reply.
    Eur J Heart Fail. 2017 Oct 18. doi: 10.1002/ejhf.1033.
    PubMed     Text format    


  183. GREENE SJ, Butler J, Fonarow GC, Subacius HP, et al
    Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial.
    Eur J Heart Fail. 2017 Oct 17. doi: 10.1002/ejhf.1019.
    PubMed     Text format     Abstract available


  184. DE BUYZERE ML
    Multi-biomarker risk stratification in heart failure: a story of diminished marginal returns after Herculean efforts?
    Eur J Heart Fail. 2017 Oct 17. doi: 10.1002/ejhf.1035.
    PubMed     Text format    


  185. GORTER TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, et al
    Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002/ejhf.1029.
    PubMed     Text format     Abstract available


  186. MAISANO F, Ruschitzka F
    Mitral interventions in heart failure: time to deliver on the promise.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002.
    PubMed     Text format    


  187. MIRO O, Tost J, Gil V, Martin-Sanchez FJ, et al
    The BRONCH-AHF study: effects on short-term outcome of nebulized bronchodilators in emergency department patients diagnosed with acute heart failure.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002/ejhf.1028.
    PubMed     Text format    


  188. SHARMA K, Tedford RJ
    Atrial fibrillation in heart failure with preserved ejection fraction: time to address the chicken and the egg.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed     Text format    


  189. BOHM M, Komajda M, Borer JS, Ford I, et al
    Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1021.
    PubMed     Text format     Abstract available


  190. LA ROVERE MT, Maestri R, Robbi E, Caporotondi A, et al
    Daytime periodic breathing during short-term laboratory recordings in heart failure patients: the iceberg tip of central sleep apnoea?
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1031.
    PubMed     Text format    


  191. MASSON S, Batkai S, Beermann J, Bar C, et al
    Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed     Text format     Abstract available


  192. MORTARA A
    Inotropes and vasopressors in acute heart failure, when the devil dresses as an angel.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1037.
    PubMed     Text format    


  193. GREENBERG B
    Jumping down the rabbit hole: unravelling the right ventricle in heart failure.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed     Text format    


  194. HANBERG JS, Rao VS, Ahmad T, Chunara Z, et al
    Inflammation and cardio-renal interactions in heart failure: a potential role for interleukin-6.
    Eur J Heart Fail. 2017 Oct 11. doi: 10.1002.
    PubMed     Text format    


  195. KAYE DM, Silvestry FE, Gustafsson F, Cleland JG, et al
    Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction.
    Eur J Heart Fail. 2017 Oct 11. doi: 10.1002.
    PubMed     Text format     Abstract available


  196. AGOSTONI P, Guazzi M
    Exercise ventilatory inefficiency in heart failure: some fresh news into the roadmap of heart failure with preserved ejection fraction phenotyping.
    Eur J Heart Fail. 2017 Oct 9. doi: 10.1002.
    PubMed     Text format    


  197. MEBAZAA A, Motiejunaite J, Gayat E, Crespo-Leiro MG, et al
    Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  198. VAN ITERSON EH, Johnson BD, Borlaug BA, Olson TP, et al
    Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  199. NUNEZ J, Sanchis J, Bayes-Genis A
    Iron status measurement in routine heart failure assessment: a call for action.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Text format    


  200. HUMMEL YM, Liu LCY, Lam CSP, Fonseca-Munoz DF, et al
    Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements.
    Eur J Heart Fail. 2017 Oct 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  201. SAVARESE G, Lund LH
    Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.
    Eur J Heart Fail. 2017 Oct 5. doi: 10.1002.
    PubMed     Text format    


  202. LAM PH, Dooley DJ, Fonarow GC, Butler J, et al
    Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
    Eur J Heart Fail. 2017 Oct 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  203. STENEMO M, Nowak C, Byberg L, Sundstrom J, et al
    Circulating proteins as predictors of incident heart failure in the elderly.
    Eur J Heart Fail. 2017 Oct 2. doi: 10.1002.
    PubMed     Text format     Abstract available


  204. METRA M
    October 2017 at a glance: phenotyping heart failure, co-morbidities, use of evidence-based therapy and new treatments.
    Eur J Heart Fail. 2017;19:1216-1217.
    PubMed     Text format    


  205. TAVAZZI L
    A brief overview of cardiac resynchronization therapy and its current use in clinical practice.
    Eur J Heart Fail. 2017;19:1280-1283.
    PubMed     Text format    


  206. CHEEMA BS, Sabbah HN, Greene SJ, Gheorghiade M, et al
    Protein turnover in the failing heart: an ever-changing landscape.
    Eur J Heart Fail. 2017;19:1218-1221.
    PubMed     Text format    


  207. SOMMER A, Kronborg MB, Nielsen JC
    Guided left ventricular lead placement for cardiac resynchronization therapy - an opportunity for image integration: reply.
    Eur J Heart Fail. 2017;19:1344.
    PubMed     Text format    


    September 2017
  208. MOTIEJUNAITE J, Celutkiene J, Mebazaa A
    The right ventricle drives the progression of heart failure.
    Eur J Heart Fail. 2017 Sep 29. doi: 10.1002.
    PubMed     Text format    


  209. WELSH P, Kou L, Yu C, Anand I, et al
    Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.
    Eur J Heart Fail. 2017 Sep 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  210. LUND LH, Trochu JN, Meyns B, Caliskan K, et al
    Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study.
    Eur J Heart Fail. 2017 Sep 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  211. LUPON J, Simpson J, McMurray JJV, de Antonio M, et al
    Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format    


  212. AGOSTONI P, Paolillo S, Mapelli M, Gentile P, et al
    Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  213. LUND LH, Svennblad B, Dahlstrom U, Stahlberg M, et al
    Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  214. VAN BILSEN M, Patel HC, Bauersachs J, Bohm M, et al
    The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  215. CANEPA M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, et al
    Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  216. BAYES-GENIS A, Lanfear DE, de Ronde MWJ, Lupon J, et al
    Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  217. HAWKINS NM
    Chronic obstructive pulmonary disease and heart failure in Europe-further evidence of the need for integrated care.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format    


  218. WOLSK E, Kaye D, Borlaug BA, Burkhoff D, et al
    Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  219. VINEREANU D, Margulescu AD
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction: reply.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  220. VAN BOVEN N, Kardys I, van Vark LC, Akkerhuis KM, et al
    Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  221. KOH AS, Tay WT, Teng THK, Vedin O, et al
    A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  222. BAYES-GENIS A, Nunez J, Lupon J
    Heart failure with mid-range ejection fraction: a transition phenotype?
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  223. SANDERSON JE, Fang F, Wei YX
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  224. WONG LL, Richards AM
    Harnessing the power of microRNAs as prognostic biomarkers in acute heart failure.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  225. TOMPKINS BA, Rieger AC, Florea V, Banerjee MN, et al
    New insights into cell-based therapy for heart failure from the CHART-1 study.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  226. KRISTENSEN SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, et al
    Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  227. MARTENS P, Verbrugge FH, Nijst P, Dupont M, et al
    Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  228. CORRA U, Agostoni PG, Anker SD, Coats AJS, et al
    Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format     Abstract available


  229. SQUIRE IB
    Biomarkers and prognostication in heart failure with reduced and preserved ejection fraction: similar but different?
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  230. BUTLER J, Stockbridge N, Gheorghiade M
    Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  231. NAGAI M, Dote K, Masaya M
    Cerebral blood flow in the central autonomic network: is there any effect of hemispheric lateralization in patients with heart failure?
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  232. GIRERD N, Rossignol P
    Performing lung ultrasound at rest and/or after an exercise stress test to better identify high-risk ambulatory patients with heart failure.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  233. RAPEZZI C, Milandri A, Lorenzini M
    The complex interplay between systolic and diastolic function at rest and during exercise in heart failure: the case of cardiac amyloidosis.
    Eur J Heart Fail. 2017 Sep 14. doi: 10.1002.
    PubMed     Text format    


  234. PATEL JN, Shah SJ
    Inorganic vs. organic nitrates for heart failure with preserved ejection fraction: it's not all in your head!
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format    


  235. TRIPPEL TD, Van Linthout S, Westermann D, Lindhorst R, et al
    Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide vs. furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format     Abstract available


  236. KALOGEROPOULOS AP, Butler J
    Heart rate in heart failure with preserved ejection fraction: target or marker?
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format    


  237. ZHANG Y, Bauersachs J, Langer HF
    Immune mechanisms in heart failure.
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format     Abstract available


  238. STEWART S
    Home is where the heart is when it comes to transitional care in heart failure, but is it the only way to improve health outcomes?
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed     Text format    


  239. PACKER M
    How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence.
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed     Text format    


  240. BOSCH L, Carluccio E, Coiro S, Gong L, et al
    Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score.
    Eur J Heart Fail. 2017 Sep 7. doi: 10.1002.
    PubMed     Text format    


  241. PLATZ E, Jhund PS, Claggett BL, Pfeffer MA, et al
    Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  242. BIERING-SORENSEN T, Querejeta Roca G, Hegde SM, Shah AM, et al
    Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  243. WAGENAAR KP, Rutten FH, Klompstra L, Bhana Y, et al
    'heartfailurematters.org', an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  244. COTTER G, Metra M, Davison BA, Jondeau G, et al
    Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


    August 2017
  245. D'ANGIOLELLA LS, Cortesi PA, Pitotti C, Ritrovato D, et al
    Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Text format    


  246. GOHAR A, Chong JPC, Liew OW, den Ruijter H, et al
    The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  247. GAYAT E, Arrigo M, Littnerova S, Sato N, et al
    Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  248. COTTER G, Cohen-Solal A, Davison BA, Mebazaa A, et al
    RELAX-AHF, BLAST-AHF, TRUE-AHF, and other important truths in acute heart failure research.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format    


  249. ZAMORA E, Lupon J, Bayes-Genis A
    Obesity in heart failure: is it time to rethink the paradox? Reply.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format    


  250. BUTLER J, Hamo CE, Filippatos G, Pocock SJ, et al
    The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  251. GREENBERG B
    Gene therapy for heart failure: time to go back to the drawing board.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format    


  252. MAGNUSSEN H, Canepa M, Zambito PE, Brusasco V, et al
    What can we learn from pulmonary function testing in heart failure?
    Eur J Heart Fail. 2017 Aug 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  253. PARISSIS J, Bistola V, Ikonomidis I, Triposkiadis F, et al
    Nitroxyl donors for acute heart failure: promising newcomers.
    Eur J Heart Fail. 2017 Aug 14. doi: 10.1002.
    PubMed     Text format    


  254. AMBROSY AP, Gheorghiade M
    Clinical profiles in acute heart failure: one size fits all or not at all?
    Eur J Heart Fail. 2017 Aug 8. doi: 10.1002.
    PubMed     Text format    


  255. AMBROSY AP, Gheorghiade M
    Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.
    Eur J Heart Fail. 2017 Aug 8. doi: 10.1002.
    PubMed     Text format    


  256. METRA M
    August 2017 at a glance: tailored treatment, acute heart failure and cardiac resynchronization.
    Eur J Heart Fail. 2017;19:969-970.
    PubMed     Text format    


    July 2017
  257. COGSWELL RJ, Norby FL, Gottesman RF, Chen LY, et al
    High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Jul 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  258. TITA C, Gilbert EM, Van Bakel AB, Grzybowski J, et al
    A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2017 Jul 5. doi: 10.1002.
    PubMed     Text format     Abstract available


    June 2017
  259. AMBROSY AP, Butler J, Gheorghiade M
    Clinical trials in acute heart failure: beginning of the end or end of the beginning?
    Eur J Heart Fail. 2017 Jun 28. doi: 10.1002.
    PubMed     Text format    


  260. BURNS KV, Gage RM, Curtin AE, Gorcsan J 3rd, et al
    Left ventricular-only pacing in heart failure patients with normal atrioventricular conduction improves global function and left ventricular regional mechanics compared with biventricular pacing: an adaptive cardiac resynchronization therapy sub-study
    Eur J Heart Fail. 2017 Jun 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  261. SHARMA A, Demissei BG, Tromp J, Hillege HL, et al
    A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure.
    Eur J Heart Fail. 2017 Jun 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  262. STEWART S
    Persistently misunderstood and malignant: the case of heart failure vs. cancer.
    Eur J Heart Fail. 2017 Jun 19. doi: 10.1002.
    PubMed     Text format    


  263. NIKOLOVSKA VUKADINOVIC A, Vukadinovic D, Borer J, Cowie M, et al
    Heart rate and its reduction in chronic heart failure and beyond.
    Eur J Heart Fail. 2017 Jun 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  264. RASTOGI A, Novak E, Platts AE, Mann DL, et al
    Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.
    Eur J Heart Fail. 2017 Jun 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  265. ZAMAN S, Zaman SS, Scholtes T, Shun-Shin MJ, et al
    The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  266. BOHM M, Laufs U, Mahfoud F, Schirmer SH, et al
    Primum non nocere: the dangers of deferring heart failure therapy.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Text format    


  267. BOSCH L, Lam CSP, Gong L, Chan SP, et al
    Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  268. MUELLER C
    Clinical utility of biomarkers in heart failure.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format    


  269. LASSUS J
    Evaluating pulmonary congestion with lung ultrasound and the need to take the next steps in heart failure.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format    


  270. DEVORE AD, Hernandez AF
    Improving heart failure health: is there a secret Swedish sauce?
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format    


  271. FERREIRA JP, Rossignol P, Machu JL, Sharma A, et al
    Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  272. HERRERO-PUENTE P, Prieto-Garcia B, Garcia-Garcia M, Llorens P, et al
    The relationship of circulating relaxin-2 concentrations with short-term prognosis in patients with acute heart failure: the RELAHF study.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  273. FILIPPATOS G, Maggioni AP, Lam CSP, Pieske-Kraigher E, et al
    Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
    Eur J Heart Fail. 2017;19:782-791.
    PubMed     Text format     Abstract available


    May 2017
  274. TEERLINK JR, Metra M, Filippatos GS, Davison BA, et al
    Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.
    Eur J Heart Fail. 2017 May 31. doi: 10.1002.
    PubMed     Text format     Abstract available


  275. DE CATERINA R
    Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater.
    Eur J Heart Fail. 2017 May 31. doi: 10.1002.
    PubMed     Text format    


  276. AHMED A, Blackman MR, White M, Anker SD, et al
    Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format    


  277. ROY B, Woo MA, Wang DJJ, Fonarow GC, et al
    Reduced regional cerebral blood flow in patients with heart failure.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  278. HARJOLA VP, Mullens W, Banaszewski M, Bauersachs J, et al
    Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  279. PLATZ E, Merz AA, Jhund PS, Vazir A, et al
    Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  280. VEGTER EL, van der Meer P, Voors AA
    Associations between volume status and circulating microRNAs in acute heart failure.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  281. CHIRINOS JA, Londono-Hoyos F, Zamani P, Beraun M, et al
    Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  282. POPESCU BA, Beladan CC, Popescu AC
    Mechanical dyssynchrony in heart failure with preserved ejection fraction: a treatment target or a dead end?
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  283. METRA M, Ravera A, Filippatos G
    Understanding worsening heart failure as a therapeutic target: another step forward?
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  284. PASCUAL-FIGAL DA
    Acute heart failure and biomarkers: time also matters, don't relax.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  285. VADUGANATHAN M, Patel RB, Butler J, Metra M, et al
    Integrating electronic health records into the study of heart failure: promises and pitfalls.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  286. VAN AELST LNL, Abraham M, Sadoune M, Lefebvre T, et al
    Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Text format    


  287. EDELMANN F, Bobenko A, Gelbrich G, Hasenfuss G, et al
    Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  288. MORBACH C, Marx A, Kaspar M, Guder G, et al
    Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  289. PINTALHAO M, Castro-Chaves P, Bettencourt P
    Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure? A reply.
    Eur J Heart Fail. 2017 May 4. doi: 10.1002.
    PubMed     Text format    


  290. MAMAS MA, Sperrin M, Watson MC, Coutts A, et al
    Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland.
    Eur J Heart Fail. 2017 May 3. doi: 10.1002.
    PubMed     Text format     Abstract available


  291. GREENE SJ, Vaduganathan M, Gheorghiade M
    Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2017 May 2. doi: 10.1002.
    PubMed     Text format    



  292. Abstracts of the Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, Paris, France, 29 April - 2 May 2017.
    Eur J Heart Fail. 2017;19 Suppl 1:5-601.
    PubMed     Text format    


  293. AHMAD T, Testani JM
    What happens to stable heart failure patients when they don't take their medicines?
    Eur J Heart Fail. 2017;19:650-651.
    PubMed     Text format    


  294. NAGELE MP
    Pulmonary artery pressure-based telemedicine in heart failure: ready for Europe?
    Eur J Heart Fail. 2017;19:670-672.
    PubMed     Text format    


  295. LEHLE K, Lubnow M, Philipp A, Foltan M, et al
    Prevalence of hemolysis and metabolic acidosis in patients with circulatory failure supported with extracorporeal life support: a marker for survival?
    Eur J Heart Fail. 2017;19 Suppl 2:110-116.
    PubMed     Text format     Abstract available


  296. ROELEVELD PP
    What is new in pediatric ECMO? 2016, a year in review.
    Eur J Heart Fail. 2017;19 Suppl 2:92-96.
    PubMed     Text format     Abstract available


  297. SOROKIN V, MacLaren G, Vidanapathirana PC, Delnoij T, et al
    Choosing the appropriate configuration and cannulation strategies for extracorporeal membrane oxygenation: the potential dynamic process of organ support and importance of hybrid modes.
    Eur J Heart Fail. 2017;19 Suppl 2:75-83.
    PubMed     Text format     Abstract available


  298. OSTADAL P, Rokyta R, Kruger A, Vondrakova D, et al
    Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial.
    Eur J Heart Fail. 2017;19 Suppl 2:124-127.
    PubMed     Text format     Abstract available


  299. DEN UIL CA, Jewbali LS, Heeren MJ, Constantinescu AA, et al
    Isolated left ventricular failure is a predictor of poor outcome in patients receiving veno-arterial extracorporeal membrane oxygenation.
    Eur J Heart Fail. 2017;19 Suppl 2:104-109.
    PubMed     Text format     Abstract available


    April 2017
  300. KOMAJDA M, Cowie MR, Tavazzi L, Ponikowski P, et al
    Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  301. CHIONCEL O, Mebazaa A, Harjola VP, Coats AJ, et al
    Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  302. KOMAJDA M, Isnard R, Cohen-Solal A, Metra M, et al
    Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  303. TEERLINK JR, Voors AA, Ponikowski P, Pang PS, et al
    Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
    Eur J Heart Fail. 2017 Apr 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  304. ANKER SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, et al
    Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Eur J Heart Fail. 2017 Apr 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  305. VINEREANU D, Margulescu AD
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction: add global longitudinal strain to the list.
    Eur J Heart Fail. 2017 Apr 19. doi: 10.1002.
    PubMed     Text format    


  306. FERREIRA JP, Mentz RJ, Pizard A, Pitt B, et al
    Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
    Eur J Heart Fail. 2017 Apr 12. doi: 10.1002.
    PubMed     Text format     Abstract available


  307. HULOT JS, Salem JE, Redheuil A, Collet JP, et al
    Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
    Eur J Heart Fail. 2017 Apr 10. doi: 10.1002.
    PubMed     Text format     Abstract available


  308. LUPON J, Diez-Lopez C, de Antonio M, Domingo M, et al
    Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  309. CHIONCEL O, Lainscak M, Seferovic PM, Anker SD, et al
    Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  310. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency and red cell indices in patients with heart failure.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  311. VENTURA HO, Messerli FH, Lavie CJ
    Observations on the blood pressure paradox in heart failure.
    Eur J Heart Fail. 2017 Apr 3. doi: 10.1002.
    PubMed     Text format    


  312. LYONS OD, Floras JS, Logan AG, Beanlands R, et al
    Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial.
    Eur J Heart Fail. 2017;19:579-587.
    PubMed     Text format     Abstract available


  313. DEFTEREOS S, Giannopoulos G, Panagopoulou V, Filippatos G, et al
    Surrogate endpoints in heart failure: (once again) use with caution.
    Eur J Heart Fail. 2017;19:563-565.
    PubMed     Text format    


  314. PLICHART M, Orvoen G, Jourdain P, Quinquis L, et al
    Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study.
    Eur J Heart Fail. 2017;19:540-548.
    PubMed     Text format     Abstract available


  315. BRISTOW MR, Sharma K, Assmann SF, Linas S, et al
    Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
    Eur J Heart Fail. 2017;19:457-465.
    PubMed     Text format     Abstract available


  316. JANSWEIJER JA, Nieuwhof K, Russo F, Hoorntje ET, et al
    Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy.
    Eur J Heart Fail. 2017;19:512-521.
    PubMed     Text format     Abstract available


  317. ZANNAD F
    Monitoring renal safety in mineralocorticoid receptor antagonist trials.
    Eur J Heart Fail. 2017;19:466-468.
    PubMed     Text format    


  318. BALLIGAND JL
    Cardiac beta3-adrenergic receptors in the clinical arena: the end of the beginning.
    Eur J Heart Fail. 2017;19:576-578.
    PubMed     Text format    


  319. SENNI M, Ferrero P, Iacovoni A
    Prognostic scores: one fits all?
    Eur J Heart Fail. 2017;19:588.
    PubMed     Text format    


  320. VAN LINTHOUT S, Tschope C
    Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy.
    Eur J Heart Fail. 2017;19:499-501.
    PubMed     Text format    


    March 2017
  321. ROM O, Aviram M
    High-density lipoprotein-associated paraoxonase 1: a possible prognostic biomarker for heart failure?
    Eur J Heart Fail. 2017 Mar 31. doi: 10.1002.
    PubMed     Text format    


  322. TSUJI K, Sakata Y, Nochioka K, Miura M, et al
    Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.
    Eur J Heart Fail. 2017 Mar 31. doi: 10.1002.
    PubMed     Text format     Abstract available


  323. LOFMAN I, Szummer K, Dahlstrom U, Jernberg T, et al
    Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
    Eur J Heart Fail. 2017 Mar 29. doi: 10.1002.
    PubMed     Text format     Abstract available


  324. MONTERO D, Flammer AJ
    Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy?
    Eur J Heart Fail. 2017 Mar 29. doi: 10.1002.
    PubMed     Text format    


  325. SCHMID FA, Schlager O, Keller P, Seifert B, et al
    Prognostic value of long-term blood pressure changes in patients with chronic heart failure.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  326. COWIE MR, Filippatos GS, Alonso Garcia ML, Anker SD, et al
    New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  327. DEVAUX Y, Creemers EE, Boon RA, Werfel S, et al
    Circular RNAs in heart failure.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  328. PIEPOLI MF
    Obesity in heart failure: is it time to rethink the paradox?
    Eur J Heart Fail. 2017 Mar 24. doi: 10.1002.
    PubMed     Text format    


  329. D'ELIA E, Iacovoni A, Vaduganathan M, Lorini FL, et al
    Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  330. BIERING-SORENSEN T, Shah SJ, Anand I, Sweitzer N, et al
    Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  331. MCDONALD K, O'Hanlon R, Savage HO, Khushaba RN, et al
    Sleep-disordered breathing in chronic heart failure is highly variable when measured remotely using a novel non-contact biomotion sensor.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  332. OLIVIER A, Pitt B, Girerd N, Lamiral Z, et al
    Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS-HF trial.
    Eur J Heart Fail. 2017 Mar 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  333. SHARMA K, Fang JC
    The heart-kidney relationship in heart failure: it's not you, it's me.
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Text format    


  334. RICKENBACHER P, Kaufmann BA, Maeder MT, Bernheim A, et al
    Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  335. DOVANCESCU S, Pellicori P, Mabote T, Torabi A, et al
    The effects of short-term omission of daily medication on the pathophysiology of heart failure.
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  336. CLELAND JG, Teerlink JR, Davison BA, Shoaib A, et al
    Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studie
    Eur J Heart Fail. 2017 Mar 10. doi: 10.1002.
    PubMed     Text format     Abstract available


  337. SLIWA K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, et al
    Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM.
    Eur J Heart Fail. 2017 Mar 8. doi: 10.1002.
    PubMed     Text format     Abstract available



  338. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
    Eur J Heart Fail. 2017;19:438.
    PubMed     Text format    


  339. DIERCKX R, Inglis SC, Clark RA, Prieto-Merino D, et al
    Telemedicine in heart failure: new insights from the Cochrane meta-analyses.
    Eur J Heart Fail. 2017;19:304-306.
    PubMed     Text format    


  340. PAN A
    The real-world evidence of heart failure co-morbidities.
    Eur J Heart Fail. 2017;19:434.
    PubMed     Text format    


  341. BRISTOW MR
    Genetic variation expressed in the brain may impact heart failure.
    Eur J Heart Fail. 2017;19:324-325.
    PubMed     Text format    


  342. MCDONALD K, Gallagher J
    The practice gap in heart failure-the elephant in the room.
    Eur J Heart Fail. 2017;19:301-303.
    PubMed     Text format    


  343. MAASS AH, DeJongste MJ, van der Meer P
    Neuromodulation for systolic heart failure: more than a placebo effect?
    Eur J Heart Fail. 2017;19:401-403.
    PubMed     Text format    



  344. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017;19:437.
    PubMed     Text format    


  345. DEMISSEI BG, Postmus D, Cleland JG, O'Connor CM, et al
    Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure.
    Eur J Heart Fail. 2017 Mar 1. doi: 10.1002.
    PubMed     Text format     Abstract available


  346. VOORS AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, et al
    Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure.
    Eur J Heart Fail. 2017 Mar 1. doi: 10.1002.
    PubMed     Text format     Abstract available


  347. PAPPALARDO F, Schulte C, Pieri M, Schrage B, et al
    Concomitant implantation of Impella(R) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock.
    Eur J Heart Fail. 2017;19:404-412.
    PubMed     Text format     Abstract available


  348. BORIANI G, Malavasi VL
    Patient outcome after implant of a cardioverter defibrillator in the 'real world': the key role of co-morbidities.
    Eur J Heart Fail. 2017;19:387-390.
    PubMed     Text format    


  349. BEHAR JM, Rajani R, Rinaldi CA
    Guided left ventricular lead placement for cardiac resynchronization therapy: an opportunity for image integration.
    Eur J Heart Fail. 2017;19:435.
    PubMed     Text format    


  350. LORUSSO R
    Are two crutches better than one? The ongoing dilemma on the effects and need for left ventricular unloading during veno-arterial extracorporeal membrane oxygenation.
    Eur J Heart Fail. 2017;19:413-415.
    PubMed     Text format    


    February 2017
  351. EMMENS JE, Ter Maaten JM, Voors AA
    Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure?
    Eur J Heart Fail. 2017 Feb 28. doi: 10.1002.
    PubMed     Text format    


  352. PELLICORI P, Urbinati A, Shah P, MacNamara A, et al
    What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
    Eur J Heart Fail. 2017 Feb 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  353. PAOLILLO S, Mapelli M, Bonomi A, Corra U, et al
    Prognostic role of beta-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database.
    Eur J Heart Fail. 2017 Feb 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  354. VAN SPALL HG, Rahman T, Mytton O, Ramasundarahettige C, et al
    Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis.
    Eur J Heart Fail. 2017 Feb 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  355. LUND LH, Carrero JJ, Farahmand B, Henriksson KM, et al
    Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study.
    Eur J Heart Fail. 2017 Feb 23. doi: 10.1002.
    PubMed     Text format     Abstract available


  356. PARASKEVAIDIS IA, Ikonomidis I, Simitsis P, Parissis J, et al
    Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study.
    Eur J Heart Fail. 2017 Feb 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  357. NAYOR M, Larson MG, Wang N, Santhanakrishnan R, et al
    The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.
    Eur J Heart Fail. 2017 Feb 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  358. GUSTAFSSON F, Rogers JG
    Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  359. SCALI MC, Cortigiani L, Simionuc A, Gregori D, et al
    Exercise-induced B-lines identify worse functional and prognostic stage in heart failure patients with depressed left ventricular ejection fraction.
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  360. EMDIN M, Aimo A, Passino C, Vergaro G, et al
    Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly?
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Text format    


  361. DEVORE AD, McNulty S, Alenezi F, Ersboll M, et al
    Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
    Eur J Heart Fail. 2017 Feb 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  362. HAMMADAH M, Kalogeropoulos AP, Georgiopoulou VV, Weber M, et al
    High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  363. COWIE MR, Simon M, Klein L, Thokala P, et al
    The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  364. LUND LH, Braunschweig F, Benson L, Stahlberg M, et al
    Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  365. HARJOLA P, Tolonen J, Boyd J, Mattila J, et al
    The role of pre-hospital management in acute heart failure.
    Eur J Heart Fail. 2017;19:287-289.
    PubMed     Text format    


  366. STEWART COATS AJ
    Early abnormalities of cerebral blood flow in mild non-ischaemic heart failure: part of a whole-body response?
    Eur J Heart Fail. 2017;19:269-270.
    PubMed     Text format    


  367. NAAR J, Jaye D, Linde C, Neuzil P, et al
    Spinal cord stimulation in heart failure: effect on disease-associated biomarkers.
    Eur J Heart Fail. 2017;19:283-286.
    PubMed     Text format    


  368. METRA M
    February 2017 at a glance: fibrosis, acute heart failure and neurologic abnormalities.
    Eur J Heart Fail. 2017;19:165-166.
    PubMed     Text format    


  369. AHMAD T, Testani JM
    Haemoconcentration as a treatment goal in heart failure: ready for prime time?
    Eur J Heart Fail. 2017;19:237-240.
    PubMed     Text format    


  370. GYONGYOSI M, Winkler J, Ramos I, Do QT, et al
    Myocardial fibrosis: biomedical research from bench to bedside.
    Eur J Heart Fail. 2017;19:177-191.
    PubMed     Text format     Abstract available


  371. PUYMIRAT E, Fagon JY, Aegerter P, Diehl JL, et al
    Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012.
    Eur J Heart Fail. 2017;19:192-200.
    PubMed     Text format     Abstract available


    January 2017
  372. DEMISSEI BG, Cotter G, Prescott MF, Felker GM, et al
    A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  373. SOKOLSKI M, Zymlinski R, Biegus J, Siwolowski P, et al
    Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  374. PAPADAKI A, Martinez-Gonzalez MA, Alonso-Gomez A, Rekondo J, et al
    Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  375. GUAZZI M
    Is sildenafil neutral on cardiopulmonary performance in group 2 pulmonary hypertension? More details for interpretation.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format    


  376. GRUSON D, Pouleur AC, Makris K, Chrysohoou C, et al
    Systematic vitamin D supplementation and monitoring: improving outcomes in heart failure?
    Eur J Heart Fail. 2017 Jan 24. doi: 10.1002.
    PubMed     Text format    


  377. DE KEULENAER GW, Segers VF, Zannad F, Brutsaert DL, et al
    The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  378. TER MAATEN JM, Rao VS, Hanberg JS, Perry Wilson F, et al
    Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  379. GUAZZI M, van Heerebeek L, Paulus WJ
    Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Text format    


  380. KOMAJDA M
    Liraglutide in heart failure: caution is needed.
    Eur J Heart Fail. 2017;19:78-79.
    PubMed     Text format    


  381. EZEKOWITZ JA, Armstrong PW
    Diabetes and heart failure in the crosshairs: where is the target?
    Eur J Heart Fail. 2017;19:66-68.
    PubMed     Text format    


  382. GWIZDALA A, Rozwadowska N, Kolanowski TJ, Malcher A, et al
    Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure.
    Eur J Heart Fail. 2017;19:148-157.
    PubMed     Text format     Abstract available


  383. BIERING-SORENSEN T, Santos M, Rivero J, McCullough SD, et al
    Left ventricular deformation at rest predicts exercise-induced elevation in pulmonary artery wedge pressure in patients with unexplained dyspnoea.
    Eur J Heart Fail. 2017;19:101-110.
    PubMed     Text format     Abstract available


  384. NAGELE MP, Steffel J, Robertson M, Singh JP, et al
    Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT.
    Eur J Heart Fail. 2017;19:80-87.
    PubMed     Text format     Abstract available


  385. TAMPAKAKIS E, Tedford RJ
    Balancing the positives and negatives of the diastolic pulmonary gradient.
    Eur J Heart Fail. 2017;19:98-100.
    PubMed     Text format    


  386. EL-BATTRAWY I, Borggrefe M, Akin I
    Predictors of mortality in Takotsubo cardiomyopathy.
    Eur J Heart Fail. 2017;19:158.
    PubMed     Text format    


    December 2016
  387. KOUDSTAAL S, Pujades-Rodriguez M, Denaxas S, Gho JM, et al
    Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people.
    Eur J Heart Fail. 2016 Dec 23. doi: 10.1002.
    PubMed     Text format     Abstract available


  388. FARMAKIS D, Triposkiadis F, Lekakis J, Parissis J, et al
    Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management.
    Eur J Heart Fail. 2016 Dec 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  389. MATYAS C, Nemeth BT, Olah A, Torok M, et al
    Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Eur J Heart Fail. 2016 Dec 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  390. ANGERMANN CE, Kaspar M, Marx A, Kittel-Schneider S, et al
    A functional variant of the neuropeptide S receptor-1 gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (INH) Study.
    Eur J Heart Fail. 2016 Dec 18. doi: 10.1002.
    PubMed     Text format     Abstract available


  391. BUNDGAARD H, Axelsson A, Hartvig Thomsen J, Sorgaard M, et al
    The-first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.
    Eur J Heart Fail. 2016 Dec 18. doi: 10.1002.
    PubMed     Text format     Abstract available


  392. SABBAH HN
    Silent disease progression in clinically stable heart failure.
    Eur J Heart Fail. 2016 Dec 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  393. SILVESTRE OM, Goncalves A, Nadruz W Jr, Claggett B, et al
    Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study.
    Eur J Heart Fail. 2016 Dec 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  394. CLELAND JG
    Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!
    Eur J Heart Fail. 2016 Dec 11. doi: 10.1002.
    PubMed     Text format    


  395. BOHM M
    Heart rate: from heart failure to chronic diseases and cancer. Is there a role for supportive care by heart rate reduction?
    Eur J Heart Fail. 2016 Dec 4. doi: 10.1002.
    PubMed     Text format    


  396. VON HAEHLING S, Papp Z, Anker SD
    ESC Heart Failure: a new journal aims to broaden heart failure views.
    Eur J Heart Fail. 2016;18:1415-1419.
    PubMed     Text format    


    November 2016
  397. DUCA F, Zotter-Tufaro C, Kammerlander AA, Panzenbock A, et al
    Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure.
    Eur J Heart Fail. 2016 Nov 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  398. REDDY YN, Borlaug BA
    Sildenafil, unbridled optimism, and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2016 Nov 21. doi: 10.1002.
    PubMed     Text format    


  399. LIU LC, Hummel YM, van der Meer P, Berger RM, et al
    Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Eur J Heart Fail. 2016 Nov 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  400. ROSSIGNOL P, Girerd N, Bakris G, Vardeny O, et al
    Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
    Eur J Heart Fail. 2016 Nov 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  401. CANNON JA, Shen L, Jhund PS, Kristensen SL, et al
    Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2016 Nov 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  402. GORTER TM, Rienstra M, van Veldhuisen DJ
    Right ventricular dysfunction in heart failure with reduced vs. preserved ejection fraction: non-identical twins?
    Eur J Heart Fail. 2016 Nov 17. doi: 10.1002.
    PubMed     Text format    


  403. GHIO S, Guazzi M, Scardovi AB, Klersy C, et al
    Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction.
    Eur J Heart Fail. 2016 Nov 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  404. ERKELENS CD, van der Wal HH, de Jong BM, Elting JW, et al
    Dynamics of cerebral blood flow in patients with mild non-ischaemic heart failure.
    Eur J Heart Fail. 2016 Nov 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  405. PACKER M, Holcomb R, Abraham WT, Anker S, et al
    Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure.
    Eur J Heart Fail. 2016 Nov 13. doi: 10.1002.
    PubMed     Text format     Abstract available


  406. HEGGERMONT WA, Papageorgiou AP, Heymans S, van Bilsen M, et al
    Metabolic support for the heart: complementary therapy for heart failure?
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  407. PARISSIS J, Nikolaou M, Mebazaa A
    The Model for End-stage Liver Disease score in acute heart failure: hepatorenal dysfunction hides behind.
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed     Text format    


  408. KAJIMOTO K, Takano T
    Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?: reply.
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed     Text format    


  409. TRIPOSKIADIS F, Pieske B, Butler J, Parissis J, et al
    Global left atrial failure in heart failure.
    Eur J Heart Fail. 2016;18:1307-1320.
    PubMed     Text format     Abstract available


  410. JHUND PS
    Geographic variation in heart failure-a matter of celebration or condemnation?
    Eur J Heart Fail. 2016;18:1329-1330.
    PubMed     Text format    


  411. METRA M
    November 2016 at a glance: the left atrium, screening for heart failure, multimodality imaging for cardiac resynchronization therapy.
    Eur J Heart Fail. 2016;18:1305-1306.
    PubMed     Text format    


  412. MEIJERS WC, de Boer RA, Ho JE
    Biomarkers to identify and prevent new-onset heart failure in the community.
    Eur J Heart Fail. 2016;18:1351-1352.
    PubMed     Text format    


  413. YANG H, Negishi K, Wang Y, Nolan M, et al
    Echocardiographic screening for non-ischaemic stage B heart failure in the community.
    Eur J Heart Fail. 2016;18:1331-1339.
    PubMed     Text format     Abstract available


  414. HAUGAA KH, Edvardsen T
    Global longitudinal strain: the best biomarker for predicting prognosis in heart failure?
    Eur J Heart Fail. 2016;18:1340-1341.
    PubMed     Text format    


    October 2016
  415. ARRIGO M, Gayat E, Parenica J, Ishihara S, et al
    Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  416. TARGHER G, Dauriz M, Laroche C, Temporelli PL, et al
    In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  417. JORSAL A, Kistorp C, Holmager P, Tougaard RS, et al
    Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  418. COIRO S, Girerd N, Rossignol P, Ferreira JP, et al
    Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myoc
    Eur J Heart Fail. 2016 Oct 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  419. DIEZ J
    Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    Eur J Heart Fail. 2016 Oct 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  420. MEIJERS WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, et al
    Variability of biomarkers in patients with chronic heart failure and healthy controls.
    Eur J Heart Fail. 2016 Oct 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  421. KLIP IT, Voors AA, Swinkels DW, Bakker SJ, et al
    Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community.
    Eur J Heart Fail. 2016 Oct 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  422. BREIDTHARDT T, Weidmann ZM, Twerenbold R, Gantenbein C, et al
    Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function.
    Eur J Heart Fail. 2016 Oct 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  423. GREENE SJ, Fonarow GC, Solomon SD, Subacius HP, et al
    Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.
    Eur J Heart Fail. 2016 Oct 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  424. NAGY AI, Venkateshvaran A, Merkely B, Lund LH, et al
    Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease.
    Eur J Heart Fail. 2016 Oct 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  425. OBOKATA M, Borlaug BA
    Right ventricular dysfunction and pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2016 Oct 13. doi: 10.1002.
    PubMed     Text format    


  426. BIEGUS J, Zymlinski R, Sokolski M, Siwolowski P, et al
    Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure.
    Eur J Heart Fail. 2016 Oct 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  427. METRA M
    October 2016 at a glance: treatment of heart failure.
    Eur J Heart Fail. 2016;18:1209-1210.
    PubMed     Text format    


  428. VADUGANATHAN M, Patel RB, Yancy CW
    Stroke prevention in heart failure and sinus rhythm: where do we go from here?
    Eur J Heart Fail. 2016;18:1267-1269.
    PubMed     Text format    


  429. CHAGGAR PS, Williams SG, Yonan N, Fildes J, et al
    Myocardial recovery with mechanical circulatory support.
    Eur J Heart Fail. 2016;18:1220-1227.
    PubMed     Text format     Abstract available


  430. REGOLI F, Bongiorni MG, Rordorf R, Santamaria M, et al
    High recurrence of device-related adverse events following transvenous lead extraction procedure in patients with cardiac resynchronization devices.
    Eur J Heart Fail. 2016;18:1270-1277.
    PubMed     Text format     Abstract available


    September 2016
  431. FITCHETT DH, Udell JA, Inzucchi SE
    Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
    Eur J Heart Fail. 2016 Sep 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  432. GORTER TM, Hoendermis ES, van Veldhuisen DJ, Voors AA, et al
    Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  433. NIEWINSKI P, Janczak D, Rucinski A, Tubek S, et al
    Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  434. DINI FL, Carluccio E, Simioniuc A, Biagioli P, et al
    Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  435. ADAMO L, Nassif ME, Novak E, LaRue SJ, et al
    Prevalence of lactic acidaemia in patients with advanced heart failure and depressed cardiac output.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  436. MARTINSON M, Bharmi R, Dalal N, Abraham WT, et al
    Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial.
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  437. MELENOVSKY V, Petrak J, Mracek T, Benes J, et al
    Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis.
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  438. SANTAS E, Nunez E, Nunez J
    Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Text format    


  439. ADAMSON PB, Ginn G, Anker SD, Bourge RC, et al
    Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials.
    Eur J Heart Fail. 2016 Sep 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  440. KITAI T, Grodin JL, Mentz RJ, Hernandez AF, et al
    Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.
    Eur J Heart Fail. 2016 Sep 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  441. IBRAHIM I, Kuan WS, Frampton C, Troughton R, et al
    Superior performance of N-terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting.
    Eur J Heart Fail. 2016 Sep 13. doi: 10.1002.
    PubMed     Text format     Abstract available


  442. ADELBORG K, Horvath-Puho E, Ording A, Pedersen L, et al
    Heart failure and risk of dementia: a Danish nationwide population-based cohort study.
    Eur J Heart Fail. 2016 Sep 9. doi: 10.1002.
    PubMed     Text format     Abstract available


  443. OMERSA D, Farkas J, Erzen I, Lainscak M, et al
    National trends in heart failure hospitalization rates in Slovenia 2004-2012.
    Eur J Heart Fail. 2016 Sep 9. doi: 10.1002.
    PubMed     Text format     Abstract available


  444. KONSTANTINIDES SV
    Trends in pregnancy outcomes in patients with pulmonary hypertension: still a long way to go.
    Eur J Heart Fail. 2016;18:1129-31.
    PubMed     Text format    


    July 2016
  445. SLIWA K, van Hagen IM, Budts W, Swan L, et al
    Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology.
    Eur J Heart Fail. 2016 Jul 7. doi: 10.1002.
    PubMed     Text format     Abstract available


    February 2016
  446. METRA M
    February 2016 at a glance. Focus issue on cardiac regeneration, medical treatment and cardiac devices.
    Eur J Heart Fail. 2016;18:127.
    PubMed     Text format    


  447. VADUGANATHAN M, Prasad V
    Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?
    Eur J Heart Fail. 2016;18:128-32.
    PubMed     Text format    


  448. STOLFO D, Tonet E, Merlo M, Barbati G, et al
    Early right ventricular response to cardiac resynchronization therapy: impact on clinical outcomes.
    Eur J Heart Fail. 2016;18:205-13.
    PubMed     Text format     Abstract available


  449. BATTY JA, Lima JA Jr, Kunadian V
    Direct cellular reprogramming for cardiac repair and regeneration.
    Eur J Heart Fail. 2016;18:145-56.
    PubMed     Text format     Abstract available


  450. SCHUSSLER-LENZ M, Beuneu C, Menezes-Ferreira M, Jekerle V, et al
    Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints.
    Eur J Heart Fail. 2016;18:133-41.
    PubMed     Text format     Abstract available


  451. VADUGANATHAN M, Goldsmith SR, Senni M, Butler J, et al
    Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
    Eur J Heart Fail. 2016;18:185-91.
    PubMed     Text format     Abstract available


    January 2016
  452. BRAMLAGE P, Swift SL, Thoenes M, Minguet J, et al
    Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Eur J Heart Fail. 2016;18:28-37.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: